Chemomab Therapeutics (CMMB) Common Equity (2017 - 2025)

Chemomab Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $12.3 million for Q4 2025.

• Quarterly Common Equity fell 8.89% year-over-year to $12.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.3 million (down 8.89% YoY) and the FY2025 annual result came in at $12.3 million, down 8.89% from the prior year.
• Common Equity was $12.3 million for Q4 2025 at Chemomab Therapeutics, up from $11.2 million in the prior quarter.
• Across five years, Common Equity topped out at $68.0 million in Q2 2021 and bottomed at $9.7 million in Q2 2025.
• A 5-year average of $31.1 million and a median of $20.0 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity jumped 469.02% — and 2023, when it sank 59.57%.
• Chemomab Therapeutics' Common Equity stood at $61.5 million in 2021, then slumped by 41.07% to $36.2 million in 2022, then plunged by 53.08% to $17.0 million in 2023, then slipped by 20.36% to $13.5 million in 2024, then declined by 8.89% to $12.3 million in 2025.
• Business Quant data shows CMMB's Common Equity at $12.3 million in Q4 2025, $11.2 million in Q3 2025, and $9.7 million in Q2 2025.